http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 14 May 2025 09:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Dermata+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2025+Financial+Results/24793800.html <p><strong>- </strong><i><strong>Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints </strong></i><strong>-</strong></p><p><strong>- </strong><i><strong>Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY® for the treatment of axillary hyperhidrosis</strong></i><strong> -</strong></p><p><i><strong>- Raised $8.8 million in gross proceeds from private placement and warrant inducement financings during the first quarter of 2025 -</strong></i></p><p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 14, 2025 / </strong><a rel="nofollow" href="https://pr.report/adsr">Dermata Therapeutics</a>, Inc. (<a rel="nofollow" href="https://pr.report/ae1m">NASDAQ:DRMA</a>)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology http://www.streetinsider.com/Press+Releases/Dermata+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2025+Financial+Results/24793800.html Wed, 14 May 2025 09:00:00 -0400 DRMA DRMAW http://www.streetinsider.com/Press+Releases/Dermata+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2025+Financial+Results/24793800.html <p><strong>- </strong><i><strong>Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints </strong></i><strong>-</strong></p><p><strong>- </strong><i><strong>Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY® for the treatment of axillary hyperhidrosis</strong></i><strong> -</strong></p><p><i><strong>- Raised $8.8 million in gross proceeds from private placement and warrant inducement financings during the first quarter of 2025 -</strong></i></p><p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 14, 2025 / </strong><a rel="nofollow" href="https://pr.report/adsr">Dermata Therapeutics</a>, Inc. (<a rel="nofollow" href="https://pr.report/ae1m">NASDAQ:DRMA</a>)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology http://www.streetinsider.com/Press+Releases/Dermata+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2025+Financial+Results/24793800.html Wed, 14 May 2025 09:00:00 -0400 DRMA DRMAW http://www.streetinsider.com/ACCESS+Newswire/Dermata+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2025+Financial+Results/24793800.html <p><strong>- </strong><i><strong>Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints </strong></i><strong>-</strong></p><p><strong>- </strong><i><strong>Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY® for the treatment of axillary hyperhidrosis</strong></i><strong> -</strong></p><p><i><strong>- Raised $8.8 million in gross proceeds from private placement and warrant inducement financings during the first quarter of 2025 -</strong></i></p><p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 14, 2025 / </strong><a rel="nofollow" href="https://pr.report/adsr">Dermata Therapeutics</a>, Inc. (<a rel="nofollow" href="https://pr.report/ae1m">NASDAQ:DRMA</a>)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology http://www.streetinsider.com/ACCESS+Newswire/Dermata+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2025+Financial+Results/24793800.html Wed, 14 May 2025 09:00:00 -0400 DRMA DRMAW http://www.streetinsider.com/ACCESS+Newswire/Dermata+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2025+Financial+Results/24793800.html <p><strong>- </strong><i><strong>Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints </strong></i><strong>-</strong></p><p><strong>- </strong><i><strong>Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY® for the treatment of axillary hyperhidrosis</strong></i><strong> -</strong></p><p><i><strong>- Raised $8.8 million in gross proceeds from private placement and warrant inducement financings during the first quarter of 2025 -</strong></i></p><p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 14, 2025 / </strong><a rel="nofollow" href="https://pr.report/adsr">Dermata Therapeutics</a>, Inc. (<a rel="nofollow" href="https://pr.report/ae1m">NASDAQ:DRMA</a>)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology http://www.streetinsider.com/ACCESS+Newswire/Dermata+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2025+Financial+Results/24793800.html Wed, 14 May 2025 09:00:00 -0400 DRMA DRMAW http://www.streetinsider.com/Corporate+News/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html <p><i><strong>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -</strong></i></p><p><i><strong>- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -</strong></i></p><p><i><strong>- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne</strong></i><strong> -</strong></p><p><span data-silink="1" rel="nofollow" href="https://pr.report/9972">Dermata Therapeutics, Inc.</span> (Nasdaq:DRMA)(Nasdaq:DRMAW), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints http://www.streetinsider.com/Corporate+News/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html Tue, 15 Apr 2025 08:35:34 -0400 DRMA DRMAW http://www.streetinsider.com/Corporate+News/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html <p><i><strong>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -</strong></i></p><p><i><strong>- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -</strong></i></p><p><i><strong>- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne</strong></i><strong> -</strong></p><p><span data-silink="1" rel="nofollow" href="https://pr.report/9972">Dermata Therapeutics, Inc.</span> (Nasdaq:DRMA)(Nasdaq:DRMAW), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints http://www.streetinsider.com/Corporate+News/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html Tue, 15 Apr 2025 08:35:34 -0400 DRMA DRMAW http://www.streetinsider.com/Trader+Talk/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html <p><i><strong>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -</strong></i></p><p><i><strong>- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -</strong></i></p><p><i><strong>- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne</strong></i><strong> -</strong></p><p><span data-silink="1" rel="nofollow" href="https://pr.report/9972">Dermata Therapeutics, Inc.</span> (Nasdaq:DRMA)(Nasdaq:DRMAW), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints http://www.streetinsider.com/Trader+Talk/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html Tue, 15 Apr 2025 08:35:34 -0400 DRMA DRMAW http://www.streetinsider.com/Trader+Talk/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html <p><i><strong>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -</strong></i></p><p><i><strong>- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -</strong></i></p><p><i><strong>- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne</strong></i><strong> -</strong></p><p><span data-silink="1" rel="nofollow" href="https://pr.report/9972">Dermata Therapeutics, Inc.</span> (Nasdaq:DRMA)(Nasdaq:DRMAW), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints http://www.streetinsider.com/Trader+Talk/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html Tue, 15 Apr 2025 08:35:34 -0400 DRMA DRMAW http://www.streetinsider.com/Hot+Corp.+News/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html <p><i><strong>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -</strong></i></p><p><i><strong>- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -</strong></i></p><p><i><strong>- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne</strong></i><strong> -</strong></p><p><span data-silink="1" rel="nofollow" href="https://pr.report/9972">Dermata Therapeutics, Inc.</span> (Nasdaq:DRMA)(Nasdaq:DRMAW), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints http://www.streetinsider.com/Hot+Corp.+News/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html Tue, 15 Apr 2025 08:35:34 -0400 DRMA DRMAW http://www.streetinsider.com/Hot+Corp.+News/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html <p><i><strong>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -</strong></i></p><p><i><strong>- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -</strong></i></p><p><i><strong>- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne</strong></i><strong> -</strong></p><p><span data-silink="1" rel="nofollow" href="https://pr.report/9972">Dermata Therapeutics, Inc.</span> (Nasdaq:DRMA)(Nasdaq:DRMAW), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints http://www.streetinsider.com/Hot+Corp.+News/Dermata%27s+%28DRMA%29+XYNGARI+Phase+3+trial+shows+significant+difference/24639648.html Tue, 15 Apr 2025 08:35:34 -0400 DRMA DRMAW http://www.streetinsider.com/Press+Releases/Dermata%E2%80%99s+XYNGARI%28TM%29+Phase+3+Trial+Hits+Statistically+Significant+Difference+at+4+Weeks/24639622.html <p><i><strong>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -</strong></i></p><p><i><strong>- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -</strong></i></p><p><i><strong>- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne</strong></i><strong> -</strong></p> <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 15, 2025 / </strong><a rel="nofollow" href="https://pr.report/9972">Dermata Therapeutics, Inc.</a> (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis http://www.streetinsider.com/Press+Releases/Dermata%E2%80%99s+XYNGARI%28TM%29+Phase+3+Trial+Hits+Statistically+Significant+Difference+at+4+Weeks/24639622.html Tue, 15 Apr 2025 08:30:00 -0400 DRMA DRMAW http://www.streetinsider.com/Press+Releases/Dermata%E2%80%99s+XYNGARI%28TM%29+Phase+3+Trial+Hits+Statistically+Significant+Difference+at+4+Weeks/24639622.html <p><i><strong>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -</strong></i></p><p><i><strong>- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -</strong></i></p><p><i><strong>- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne</strong></i><strong> -</strong></p> <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 15, 2025 / </strong><a rel="nofollow" href="https://pr.report/9972">Dermata Therapeutics, Inc.</a> (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis http://www.streetinsider.com/Press+Releases/Dermata%E2%80%99s+XYNGARI%28TM%29+Phase+3+Trial+Hits+Statistically+Significant+Difference+at+4+Weeks/24639622.html Tue, 15 Apr 2025 08:30:00 -0400 DRMA DRMAW http://www.streetinsider.com/ACCESS+Newswire/Dermata%E2%80%99s+XYNGARI%28TM%29+Phase+3+Trial+Hits+Statistically+Significant+Difference+at+4+Weeks/24639622.html <p><i><strong>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -</strong></i></p><p><i><strong>- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -</strong></i></p><p><i><strong>- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne</strong></i><strong> -</strong></p> <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 15, 2025 / </strong><a rel="nofollow" href="https://pr.report/9972">Dermata Therapeutics, Inc.</a> (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis http://www.streetinsider.com/ACCESS+Newswire/Dermata%E2%80%99s+XYNGARI%28TM%29+Phase+3+Trial+Hits+Statistically+Significant+Difference+at+4+Weeks/24639622.html Tue, 15 Apr 2025 08:30:00 -0400 DRMA DRMAW http://www.streetinsider.com/ACCESS+Newswire/Dermata%E2%80%99s+XYNGARI%28TM%29+Phase+3+Trial+Hits+Statistically+Significant+Difference+at+4+Weeks/24639622.html <p><i><strong>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -</strong></i></p><p><i><strong>- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -</strong></i></p><p><i><strong>- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne</strong></i><strong> -</strong></p> <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 15, 2025 / </strong><a rel="nofollow" href="https://pr.report/9972">Dermata Therapeutics, Inc.</a> (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis http://www.streetinsider.com/ACCESS+Newswire/Dermata%E2%80%99s+XYNGARI%28TM%29+Phase+3+Trial+Hits+Statistically+Significant+Difference+at+4+Weeks/24639622.html Tue, 15 Apr 2025 08:30:00 -0400 DRMA DRMAW http://www.streetinsider.com/Press+Releases/Dermata+Therapeutics+Announces+Exercise+of+Warrants+for+%246.2+Million+in+Gross+Proceeds+Priced+At-the-Market+Under+Nasdaq+Rules/24561344.html <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 27, 2025 / </strong>Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company's common stock, having exercise prices of $1.58 and $4.91 per share, issued by Dermata in September 2024 (with respect to 3,825,138 warrants) and May 2024 (with respect to 1,009,332 warrants), at a http://www.streetinsider.com/Press+Releases/Dermata+Therapeutics+Announces+Exercise+of+Warrants+for+%246.2+Million+in+Gross+Proceeds+Priced+At-the-Market+Under+Nasdaq+Rules/24561344.html Thu, 27 Mar 2025 20:15:00 -0400 DRMA DRMAW http://www.streetinsider.com/Press+Releases/Dermata+Therapeutics+Announces+Exercise+of+Warrants+for+%246.2+Million+in+Gross+Proceeds+Priced+At-the-Market+Under+Nasdaq+Rules/24561344.html <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 27, 2025 / </strong>Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company's common stock, having exercise prices of $1.58 and $4.91 per share, issued by Dermata in September 2024 (with respect to 3,825,138 warrants) and May 2024 (with respect to 1,009,332 warrants), at a http://www.streetinsider.com/Press+Releases/Dermata+Therapeutics+Announces+Exercise+of+Warrants+for+%246.2+Million+in+Gross+Proceeds+Priced+At-the-Market+Under+Nasdaq+Rules/24561344.html Thu, 27 Mar 2025 20:15:00 -0400 DRMA DRMAW http://www.streetinsider.com/ACCESS+Newswire/Dermata+Therapeutics+Announces+Exercise+of+Warrants+for+%246.2+Million+in+Gross+Proceeds+Priced+At-the-Market+Under+Nasdaq+Rules/24561344.html <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 27, 2025 / </strong>Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company's common stock, having exercise prices of $1.58 and $4.91 per share, issued by Dermata in September 2024 (with respect to 3,825,138 warrants) and May 2024 (with respect to 1,009,332 warrants), at a http://www.streetinsider.com/ACCESS+Newswire/Dermata+Therapeutics+Announces+Exercise+of+Warrants+for+%246.2+Million+in+Gross+Proceeds+Priced+At-the-Market+Under+Nasdaq+Rules/24561344.html Thu, 27 Mar 2025 20:15:00 -0400 DRMA DRMAW http://www.streetinsider.com/ACCESS+Newswire/Dermata+Therapeutics+Announces+Exercise+of+Warrants+for+%246.2+Million+in+Gross+Proceeds+Priced+At-the-Market+Under+Nasdaq+Rules/24561344.html <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 27, 2025 / </strong>Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company's common stock, having exercise prices of $1.58 and $4.91 per share, issued by Dermata in September 2024 (with respect to 3,825,138 warrants) and May 2024 (with respect to 1,009,332 warrants), at a http://www.streetinsider.com/ACCESS+Newswire/Dermata+Therapeutics+Announces+Exercise+of+Warrants+for+%246.2+Million+in+Gross+Proceeds+Priced+At-the-Market+Under+Nasdaq+Rules/24561344.html Thu, 27 Mar 2025 20:15:00 -0400 DRMA DRMAW http://www.streetinsider.com/Corporate+News/Dermata+Therapeutics%2C+Inc+%28DRMA%29+Reports+XYNGARI+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555651.html <p><span data-silink="1" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4392681-1&amp;h=1814492621&amp;u=https%3A%2F%2Fwww.dermatarx.com%2F&amp;a=Dermata+Therapeutics%2C+Inc." rel="nofollow"><span value="NASDAQ-NMS:DRMA" idsrc="xmltag.org">Dermata Therapeutics, Inc.</span></span> (Nasdaq: DRMA, DRMAW) today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARI^TM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment.</p><p>The XYNGARI™ Phase 3 <b>S</b>pongilla <b>T</b>reatment for <b>A</b>cne <b>R</b>esearch (STAR-1) trial met all three primary endpoints by achieving a statistically significant difference when compared with placebo after 12 weeks of once weekly treatments with XYNGARI™.</p><p>"I believe having http://www.streetinsider.com/Corporate+News/Dermata+Therapeutics%2C+Inc+%28DRMA%29+Reports+XYNGARI+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555651.html Thu, 27 Mar 2025 08:01:13 -0400 DRMA DRMAW http://www.streetinsider.com/Corporate+News/Dermata+Therapeutics%2C+Inc+%28DRMA%29+Reports+XYNGARI+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555651.html <p><span data-silink="1" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4392681-1&amp;h=1814492621&amp;u=https%3A%2F%2Fwww.dermatarx.com%2F&amp;a=Dermata+Therapeutics%2C+Inc." rel="nofollow"><span value="NASDAQ-NMS:DRMA" idsrc="xmltag.org">Dermata Therapeutics, Inc.</span></span> (Nasdaq: DRMA, DRMAW) today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARI^TM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment.</p><p>The XYNGARI™ Phase 3 <b>S</b>pongilla <b>T</b>reatment for <b>A</b>cne <b>R</b>esearch (STAR-1) trial met all three primary endpoints by achieving a statistically significant difference when compared with placebo after 12 weeks of once weekly treatments with XYNGARI™.</p><p>"I believe having http://www.streetinsider.com/Corporate+News/Dermata+Therapeutics%2C+Inc+%28DRMA%29+Reports+XYNGARI+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555651.html Thu, 27 Mar 2025 08:01:13 -0400 DRMA DRMAW http://www.streetinsider.com/FDA/Dermata+Therapeutics%2C+Inc+%28DRMA%29+Reports+XYNGARI+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555651.html <p><span data-silink="1" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4392681-1&amp;h=1814492621&amp;u=https%3A%2F%2Fwww.dermatarx.com%2F&amp;a=Dermata+Therapeutics%2C+Inc." rel="nofollow"><span value="NASDAQ-NMS:DRMA" idsrc="xmltag.org">Dermata Therapeutics, Inc.</span></span> (Nasdaq: DRMA, DRMAW) today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARI^TM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment.</p><p>The XYNGARI™ Phase 3 <b>S</b>pongilla <b>T</b>reatment for <b>A</b>cne <b>R</b>esearch (STAR-1) trial met all three primary endpoints by achieving a statistically significant difference when compared with placebo after 12 weeks of once weekly treatments with XYNGARI™.</p><p>"I believe having http://www.streetinsider.com/FDA/Dermata+Therapeutics%2C+Inc+%28DRMA%29+Reports+XYNGARI+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555651.html Thu, 27 Mar 2025 08:01:13 -0400 DRMA DRMAW http://www.streetinsider.com/FDA/Dermata+Therapeutics%2C+Inc+%28DRMA%29+Reports+XYNGARI+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555651.html <p><span data-silink="1" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4392681-1&amp;h=1814492621&amp;u=https%3A%2F%2Fwww.dermatarx.com%2F&amp;a=Dermata+Therapeutics%2C+Inc." rel="nofollow"><span value="NASDAQ-NMS:DRMA" idsrc="xmltag.org">Dermata Therapeutics, Inc.</span></span> (Nasdaq: DRMA, DRMAW) today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARI^TM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment.</p><p>The XYNGARI™ Phase 3 <b>S</b>pongilla <b>T</b>reatment for <b>A</b>cne <b>R</b>esearch (STAR-1) trial met all three primary endpoints by achieving a statistically significant difference when compared with placebo after 12 weeks of once weekly treatments with XYNGARI™.</p><p>"I believe having http://www.streetinsider.com/FDA/Dermata+Therapeutics%2C+Inc+%28DRMA%29+Reports+XYNGARI+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555651.html Thu, 27 Mar 2025 08:01:13 -0400 DRMA DRMAW http://www.streetinsider.com/Press+Releases/BREAKING%3A+Dermata%27s+XYNGARI%E2%84%A2+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555621.html <div class="xn-content"> <p class="prntac"><i>- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne -</i></p> <p class="prntac"><i>- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne</i> -</p> <p class="prntac"><i>- Over 30 million acne patients seek treatment in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> each year -</i></p> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>March 26, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4392681-1&amp;h=1814492621&amp;u=https%3A%2F%2Fwww.dermatarx.com%2F&amp;a=Dermata+Therapeutics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:DRMA" idsrc="xmltag.org" >Dermata Therapeutics, Inc.</span></a> (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, http://www.streetinsider.com/Press+Releases/BREAKING%3A+Dermata%27s+XYNGARI%E2%84%A2+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555621.html Thu, 27 Mar 2025 08:00:00 -0400 A.06822034 A.50213550 DRMA DRMAW O.20026344 O.28730328 O.35229939 http://www.streetinsider.com/Press+Releases/BREAKING%3A+Dermata%27s+XYNGARI%E2%84%A2+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555621.html <div class="xn-content"> <p class="prntac"><i>- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne -</i></p> <p class="prntac"><i>- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne</i> -</p> <p class="prntac"><i>- Over 30 million acne patients seek treatment in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> each year -</i></p> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>March 26, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4392681-1&amp;h=1814492621&amp;u=https%3A%2F%2Fwww.dermatarx.com%2F&amp;a=Dermata+Therapeutics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:DRMA" idsrc="xmltag.org" >Dermata Therapeutics, Inc.</span></a> (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, http://www.streetinsider.com/Press+Releases/BREAKING%3A+Dermata%27s+XYNGARI%E2%84%A2+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555621.html Thu, 27 Mar 2025 08:00:00 -0400 A.06822034 A.50213550 DRMA DRMAW O.20026344 O.28730328 O.35229939 http://www.streetinsider.com/Press+Releases/BREAKING%3A+Dermata%27s+XYNGARI%E2%84%A2+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555621.html <div class="xn-content"> <p class="prntac"><i>- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne -</i></p> <p class="prntac"><i>- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne</i> -</p> <p class="prntac"><i>- Over 30 million acne patients seek treatment in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location> each year -</i></p> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>March 26, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4392681-1&amp;h=1814492621&amp;u=https%3A%2F%2Fwww.dermatarx.com%2F&amp;a=Dermata+Therapeutics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:DRMA" idsrc="xmltag.org" >Dermata Therapeutics, Inc.</span></a> (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, http://www.streetinsider.com/Press+Releases/BREAKING%3A+Dermata%27s+XYNGARI%E2%84%A2+Phase+3+Trial+Topline+Data+Meets+All+Primary+Endpoints/24555621.html Thu, 27 Mar 2025 08:00:00 -0400 A.06822034 A.50213550 DRMA DRMAW O.20026344 O.28730328 O.35229939